Dominique Brard joins Ipsen as Executive Vice President of Human Resources

19 December 2013

French pharmaceutical company Ipsen (Euronext: IPN) has announced the appointment of Dominique Brard as Executive Vice President in charge of human resources of the Ipsen group in place of Etienne de Blois.

Ms Brard will now be a member of Ipsen’s Executive Committee. She will take up her new position on January 6, reporting directly to Christel Bories, deputy CEO of the Ipsen group.

Ipsen said in a statement that the company will benefit from Ms Brard’s knowledge of other industries and her expertise in supporting transformation, developing organizations, and fostering talent.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK